UCBJF News and Press, Ucb Sa Npv From 07/31/21

UCB SA (UCBJF) Q2 2021 Results Conference Call July 29, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl - E...

Homology Medicines (FIXX) announces the promotion of Tim Kelly to chief operating officer from previously held role of the company's chief technical operating officer.The change in effective immediately.Prior to joining Homology Medicines, Kelly has held leadership positions at Shire (SH...

UCB SA (UCBJF) Q4 2020 Results Conference Call February 25, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl...

The following slide deck was published by UCB SA in conjunction with their 2020 Q4 earnings call. For further details see: UCB SA 2020 Q4 - Results - Earnings Call Presentation

The European Medicines Agency's advisory group CHMP has adopted positive opinions backing extended uses of the following drugs:Amgen's (AMGN) Kyprolis (carfilzomib): in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone or with dexamethasone alone for the trea...

Aimed at beefing up its activities in gene therapies, UCB SA (UCBJF) has acquired Leuven, Belgium-based Handl Therapeutics BV, a developer of AAV gene therapies for neurodegenerative disorders, for an undisclosed sum.It has also inked an R&D collaboration agreement with Alachua, FL-based ...

Quick Take Inhibikase Therapeutics ( IKT ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for neurodegenerative and cancer diseases. IKT is still at a ...

UCB S.A. ( OTCPK:UCBJF ) inks an agreement with Roche ( OTCQX:RHHBY ) and Genentech granting the parties exclusive global development and commercialization rights to UCB107 for the potential treatment of Alzheimer's disease (AD). More news on: UCB SA, Roche Holding AG, UCB SA, Health...

- UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further potentia...

UCB SA (UCBJF) Q2 2020 Earnings Conference Call July 27, 2020 8:00 AM ET Company Participants Antje Witte - Vice President Investor Relations Jean-Christophe Tellier - Chief Executive Officer and Executive Director Iris Löw-Friedrich - Chief Medical Officer Emmanuel Caeyma...